These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 25749422)

  • 1. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
    Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
    Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
    Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
    Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
    Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
    Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
    Kapuria V; Peterson LF; Fang D; Bornmann WG; Talpaz M; Donato NJ
    Cancer Res; 2010 Nov; 70(22):9265-76. PubMed ID: 21045142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Mediates the Reversal Effect of Verapamil on Chemo-Resistance to Adriamycin of Hepatocellular Carcinoma.
    Yang G; Fan G; Zhang T; Ma K; Huang J; Liu M; Teng X; Xu K; Fan P; Cheng D
    Med Sci Monit; 2018 Apr; 24():2072-2082. PubMed ID: 29627846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
    Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
    Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.
    Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4883-4894. PubMed ID: 38165424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression.
    Yang Y; He J; Chen J; Lin L; Liu Y; Zhou C; Su Y; Wei H
    Biomed Res Int; 2019; 2019():8207056. PubMed ID: 31976328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
    Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
    J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
    Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
    J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
    Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
    World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma and chemotherapy: the role of p53.
    Brito AF; Abrantes AM; Pinto-Costa C; Gomes AR; Mamede AC; Casalta-Lopes J; Gonçalves AC; Sarmento-Ribeiro AB; Tralhão JG; Botelho MF
    Chemotherapy; 2012; 58(5):381-6. PubMed ID: 23257706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
    Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
    Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues.
    Wang L; Wang YM; Xu S; Wang WG; Chen Y; Mao JY; Tian BL
    Mol Med Rep; 2015 Oct; 12(4):5274-80. PubMed ID: 26135967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
    Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
    Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation.
    Liu L; Chen X; Xie S; Zhang C; Qiu Z; Zhu F
    Hepatology; 2012 Nov; 56(5):1760-9. PubMed ID: 22576474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
    Chan KT; Lung ML
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
    Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
    Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.